Drug Trial Radar · NCT05610085
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
133
Planned (sponsor's estimate)
Start
Mar 24, 2023
Primary completion
Jul 1, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- University of California, San DiegoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Minnesota; Rady Children's Hospital, San Diego; Auckland City Hospital; University of Auckland, New Zealand; Middlemore Hospital, New Zealand; Waikato Hospital
- First posted
- Nov 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 1 month
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to determine the maximum safe tolerated dose of LEV in the treatment of neonatal seizures. Our hypothesis is that optimal dosing of Levetiracetam (LEV) to treat neonatal seizures is significantly greater than 60mg/kg. This study will be an open label dose-escalation, preliminary safety and efficacy study. There will be a randomized control treatment component. Infants recognized as having neonatal seizures or as being at risk of developing seizures will be recruited and started on continuous video EEG monitoring (CEEG). Eligibility will be confirmed and consent will be obtained. In the first 2 phases of the study, neurologists will identify neonates with mild-moderate seizure burden (less than 8 minutes cumulative seizure activity per hour), appropriate for study with LEV, and exclude patients with higher seizure burden where treatment with PHB is more appropriate. Phase 3 of the dose escalation will only proceed if additional efficacy of LEV has been demonstrated in phases 1 and 2. In Phase 3 we will recruit neonates with seizures of greater severity up to 20 minute seizure burden/hour. This will make the final results of study more generalizable. If seizures are confirmed, enrolled subjects will receive 60mg/kg of LEV. Subjects whose seizures persist or recur 15 minutes after the first infusion is complete, subjects will then be randomized in the dose escalation study. Patients in the dose escalation study will be randomly assigned to receive either higher dose LEV or treatment with the control drug PHB in a 3:1 allocation ratio, stratified by site. Funding Source- FDA OOPD
Conditions
- Neonatal Seizure
- Neonatal Encephalopathy
- Hypoxic-Ischemic Encephalopathy
- Seizure Newborn
Interventions
Levetiracetam InjectionDrug
Neonates will be treated with intravenous levetiracetam 60mg/kg for first line management of seizures, and if seizures persist will be randomized to receive higher dose Levetiracetam or standard of care phenobarbital
Phenobarbital Sodium InjectionDrug
Standard of care for neonatal seizures
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint is the maximum safe and tolerated dose of LevetiracetamTime frame: 4 years
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
University of California, San Diego
San Diego, California · Completed
University of Minnesota
Minneapolis, Minnesota · Recruiting
Auckland City Hospital
Auckland, Auckland, New Zealand · Recruiting
Middlemore Hospital
Auckland, Auckland, New Zealand · Recruiting
Health New Zealand, Te Whatu Ora - Waikato Hospital
Hamilton, Waikato Region, New Zealand · Recruiting
Capital and Coast District Health Board, Te Whatu Ora, Health New Zealand
Wellington, Wellington Region, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.